Pfizer Inc. $PFE Shares Sold by M&T Bank Corp

Key Points

• M&T Bank Corp cut its stake in Pfizer by 89.8% in Q4, selling 2,115,466 shares and leaving 240,613 shares valued at about $5.99 million.
• Pfizer beat Q4 estimates, reporting EPS of $0.66 versus $0.57 expected and revenue of $17.56 billion versus $16.93 billion, though revenue was down 1.2% year‑over‑year.
• Pfizer announced a quarterly dividend of $0.43 (ex‑dividend May 8, payable June 12), implying a 6.4% yield but a high payout ratio of ~126%, which raises sustainability questions.

M&T Bank Corp cut its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 89.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 240,613 shares of the biopharmaceutical company's stock after selling 2,115,466 shares during the period. M&T Bank Corp's holdings in Pfizer were worth $5,991,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the business. Horizon Financial Services LLC lifted its position in shares of Pfizer by 174.8% during the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 645 shares during the last quarter. YANKCOM Partnership acquired a new position in shares of Pfizer in the 4th quarter worth $28,000. Grey Fox Wealth Advisors LLC acquired a new stake in shares of Pfizer during the third quarter worth $29,000. Darwin Wealth Management LLC purchased a new stake in shares of Pfizer during the second quarter valued at $32,000. Finally, True Wealth Design LLC lifted its holdings in shares of Pfizer by 302.5% during the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company's stock valued at $33,000 after purchasing an additional 974 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Trading Up 1.3%

NYSE:PFE opened at $27.01 on Friday. The stock has a market cap of $153.56 billion, a PE ratio of 19.86 and a beta of 0.43. Pfizer Inc. has a fifty-two week low of $21.97 and a fifty-two week high of $28.75. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. The stock's 50-day moving average is $27.23 and its two-hundred day moving average is $26.06.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.57 by $0.09. The business had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm's revenue was down 1.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.63 earnings per share. As a group, equities research analysts forecast that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be given a $0.43 dividend. The ex-dividend date is Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a yield of 6.4%. Pfizer's dividend payout ratio is presently 126.47%.

Analysts Set New Price Targets

A number of brokerages recently weighed in on PFE. Argus raised Pfizer from a "hold" rating to a "buy" rating and set a $35.00 price target on the stock in a research note on Monday, March 2nd. Royal Bank Of Canada reiterated an "underperform" rating and issued a $25.00 target price on shares of Pfizer in a report on Monday, April 20th. HSBC lifted their target price on shares of Pfizer from $29.00 to $32.00 and gave the stock a "buy" rating in a research report on Tuesday, March 17th. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Pfizer in a research note on Thursday, January 22nd. Finally, Cantor Fitzgerald reiterated a "neutral" rating and set a $27.00 price objective on shares of Pfizer in a research report on Wednesday, February 4th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, fourteen have given a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $28.48.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Board declared a $0.43 Q2 dividend (payable June 12; ex-div May 8), reinforcing Pfizer’s long track record of income (350th consecutive quarterly dividend) and supporting demand from income-minded investors. Pfizer Declares Second-Quarter 2026 Dividend
• Positive Sentiment: Seagen acquisition appears to be contributing to growth and a stronger oncology franchise (Antibody‑Drug Conjugates), supporting medium-term revenue upside as Pfizer expands cancer capabilities. Pfizer Inc. (PFE): One of the Best Safe Stocks to Invest in for Beginners
• Positive Sentiment: GLP‑1 obesity program momentum — Phase 2b monthly GLP‑1 data and plans for a large clinical program provide optionality beyond legacy drugs and could open a new growth engine if later‑stage trials succeed. Pfizer’s Monthly GLP-1 Push Tests Balance Between Obesity Growth And Dividends
• Positive Sentiment: Multiple early‑stage pipeline advances (completion of a China Phase 1 for a heart‑failure candidate, new gastric‑emptying study for an obesity asset, new Phase 1 cancer and liver studies) add cadence and long‑term upside to the pipeline. Pfizer Advances Early-Stage Heart Failure Candidate With Completion Of Chinese Phase 1 Study
• Neutral Sentiment: Pfizer released results from its 2026 shareholder meeting — largely procedural items that don’t materially change near‑term fundamentals. Pfizer Unveils 2026 Shareholder Meeting Results
• Neutral Sentiment: Bristol Myers and Pfizer will make Eliquis available through Mark Cuban’s Cost Plus pharmacy starting April 27 — improves patient access but raises questions about pricing/volume tradeoffs; watch margin impact. Bristol Myers, Pfizer to offer blockbuster blood thinner through Mark Cuban's online pharmacy
• Neutral Sentiment: Broader industry news — competitors (e.g., Eli Lilly, Novo Nordisk) continue to shape the obesity/GLP‑1 landscape; this is both competitive risk and market validation for Pfizer’s obesity push. Eli Lilly's new GLP-1 pill vs. Wegovy, JPMorgan initiates coverage on Hims
• Negative Sentiment: Pfizer ended a Phase 1 cancer trial, trimming part of its oncology pipeline — a reminder that not all program investments convert to later‑stage value and a near‑term negative headline. Pfizer Ends Early-Stage Cancer Trial, Trimming Its Oncology Pipeline
• Negative Sentiment: Analyst skepticism persists (Barclays remains negative; consensus leans to “hold”), which can cap upside until clearer revenue/cost trajectories emerge. Barclays Remains a Sell on Pfizer (PFE)

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.